What is HC Wainwright’s Estimate for BDTX Q1 Earnings?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Equities researchers at HC Wainwright lowered their Q1 2025 EPS estimates for Black Diamond Therapeutics in a report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.32) per share for the quarter, down from their prior estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03.

BDTX has been the topic of a number of other research reports. Stifel Nicolaus cut their target price on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Black Diamond Therapeutics has an average rating of “Buy” and an average price target of $14.60.

Black Diamond Therapeutics Trading Up 2.4 %

Shares of BDTX opened at $1.72 on Thursday. The firm’s 50-day moving average price is $2.17 and its 200-day moving average price is $2.93. The firm has a market capitalization of $97.46 million, a price-to-earnings ratio of -1.29 and a beta of 2.52. Black Diamond Therapeutics has a 1-year low of $1.59 and a 1-year high of $7.66.

Institutional Investors Weigh In On Black Diamond Therapeutics

Hedge funds have recently bought and sold shares of the business. Walleye Capital LLC bought a new stake in Black Diamond Therapeutics during the third quarter worth about $49,000. Intech Investment Management LLC purchased a new position in Black Diamond Therapeutics in the third quarter worth about $56,000. D. E. Shaw & Co. Inc. purchased a new position in Black Diamond Therapeutics in the fourth quarter worth about $37,000. JPMorgan Chase & Co. raised its holdings in Black Diamond Therapeutics by 429.6% in the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock worth $41,000 after buying an additional 15,355 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Black Diamond Therapeutics in the fourth quarter worth about $42,000. Institutional investors own 95.47% of the company’s stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.